Searched for
AMGEN INVESTMENT IN INDIA
Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...- Three more global companies set to hop on India’s GCC trainVideotelephony firm Zoom, telecom giant T-Mobile and low-cost airline Southwest Airlines are among the latest global companies considering ...
- Unstructured clinical data opens fresh market for AI firmsUnstructured clinical data, comprising 80% of health information, presents a significant market opportunity for AI-driven solutions. Expert...
- Amgen to invest $200 million in India site, CEO saysAmgen will invest $200 million in its new technology centre in Hyderabad, India, this year, with plans for further investments. The centre,...
- Amgen expands global capability centre in Hyderabad with 500,000 sq ft leaseAmgen leases 500,000 sq ft in Hyderabad to establish its first global capability centre, enhancing its office space in the city. The new ce...
- Telangana CM secures over Rs 31,500 cr plans in US tour, leaves for South KoreaThe delegation held Roundtable Conferences on business, AI and semiconductors, spanning coast to coast, and also met with CEOs, founders an...
- Biotech giant Amgen plans to open to technology & innovation centre in HyderabadUS biotech giant Amgen announced plans to open a new technology and innovation site in Hyderabad, India. The site will be located in HITEC ...
- The margin of safety: the ten-billion-dollar lesson from AmgenA notable book that emphasized the importance of corporate culture by looking at successful companies (stock price performance as a guide) ...
- Cadila Pharma appoints Ashraf Allam global COOAllam, who served as the CEO at the Public Investment Fund prior to joining Cadila Pharmaceuticals, will report to Group Chairman and Manag...
- Syngene can put on muscle as global pharma companies increase R&D spendingSyngene is a fully integrated CRAMS company and Biocon has around 70% stake in it. Syngene also has a wholly-owned subsidiary in the US.
- Syngene's CEO Jonathan Hunt says India now offers intellectual arbitrage to firms“A young scientist joining a company like Syngene can travel the world scientifically without ever having to leave Bengaluru. It provides o...
- Top government officials, leaders from industry, academicians to take part in India-US Biopharma and Healthcare SummitNITI Aayog CEO Amitabh Kant, Pfizer CEO Dr Alberta Bourla, National Institutes of Health (NIH) Director Dr Francis Collins and Food and Dru...
- Pharma sector needs global collaboration: Industry leaders, government officialsAhead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...
- Twelve stocks in focus on Wednesday, 07 September 2016The Indian market is expected to open higher. Here is a list of top twelve stocks that are likely to be in focus today.
- How Dr Reddy’s is rebooting its biosimilars playDr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.
- Why Indian entrepreneurs are missing at the top in both biotech and consumer tech cos in Silicon ValleyTechnology becomes more and more important as consumer technology companies grow. Facebook and Twitter now use analytics intensely.
- Cipla to partner Chinese co in selling Roche, Amgen drug clonesCipla, the Indian drugmaker that built a $1-billion business making generic HIV treatments, aims to sell copies of Roche Holding's and Amge...
- Parag Saxena to raise $1.5 bn for Asia fund with India focusParag Saxena, one of the leading venture capitalists in the US and an early investor in Starbucks, is raising $1.5 billion for a dedicated ...
- Dr Reddy's developing 8 more biotech drugsDr. Reddy's Laboratories developing eight generic medicines using biotechnology.
- Global pharma cos explore contract research in IndiaA new chapter is being added to the Indian pharma story. Leading global pharma and biotechnology firms, such as Schering-Plough, Bristol-My...
Load More
